Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(RDA-0537) Dendritic cell vaccine (DC/PC3) for prostate cancer


 Return to List of Clinical Studies
 Return to List of Protocols for Cancer
A Phase I/II Study of Autologous Dendritic Cells Pulsed with Apoptotic Tumor Cells (DC/PC3) Administered Subcutaneously to Prostate cancer Patients (RDA-0537)

Principal Investigator:
Robert B. Darnell M.D., Ph.D.

Investigators:

Contact Information:
Mayu Frank, ANP
Rockefeller University
1230 York Avenue
New York, NY 10065
Telephone: 212-327-7443
Email: frankm@rockefeller.edu
Enrollment Status:
Closed to Enrollment

Brief Summary of Protocol:
This is a dendritic cell vaccine study for prostate cancer patients. Vaccine will be made from each individual participant’s white blood cells. Patients will receive vaccine and 3 boosters every 2 weeks in hopes of boosting the immune system against the patient’s own cancer cells. This is an outpatient study.



Detailed Description of Protocol:




What specifically makes a person eligible for the study?
You may be eligible to enter this study:

Diagnosis of prostate cancer

Rising PSA after definitive local therapy or with hormone therapy

No neurologic metastasis

No history of autoimmune diseases

HLA A2.1 positive



Gender:
Male

Age(s):
18 years and older

Children permitted to participate:
No

Potential Benefits.....
As this is a phase I/II study, there are no known benefits as of yet.



Compensation:
None